Adelaide, Australia: Bionomics Limited (ASX: BNO) today announced the extension of the employment contract of Dr Deborah Rathjen, as CEO and Managing Director until 7 August 2011.
Dr Peter Jonson, Chairman of Bionomics said: The Board is pleased to have extended Dr. Deborah Rathjen’s contract, she is a respected member of our team and in the broader biotechnology and pharmaceutical community. She has successfully led Bionomics through a number of company changing events and achieved significant uplift in share value.”
Dr Rathjen has been instrumental in transforming Bionomics from a genomics company to a fully integrated drug discovery company with clinical stage compounds, through a strategy combing merger and acquisition activity and organic growth. This is best evidenced in Dr. Rathjen’s ability to secure and oversee the integrations of the lliad and Neurofit acquisitions.
The strength of Bionomics’ pipeline, which includes anti-cancer agent BNC105 and anxiolytic BNC210, reflects Dr. Rathjen’s commitment and persistence in the execution of Bionomics’ strategy.
Dr. Rathjen has also successfully led a number of significant drug discovery partnership deals for Bionomics. Recently, she secured a development and license agreement On Bionomics’ Multiple Sclerosis program with Merck Serono. In 2006 she successfully converted Bionomics’ 2002 co-development agreement with Genmab A/S covering angiogenesis drug targets to a licensing agreement which included an upfront payment development milestones and royalties on product sales. A preclinical milestone under the agreement was paid by Genmab earlier this year.
Dr Rathjen said: “Bionomics has a great team of experienced and highly motivated people focused on its success. We have a number of important milestones ahead which will continue to define Bionomics as a rising star and I feel privileged to continue at the helm.”
FOR FURTHER INFORMATION PLEASE CONTACT:
Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 / 0418 160 425
+612 9237 2800 / 0414 388 955